A Single-Blinded Assessment of the Short-Term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-Patient Subjects With Parkinson's Disease.
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Cabergoline; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacodynamics
- 29 Jun 2011 New source identified and integrated (European Clinical Trials Database)
- 01 Sep 2009 Planned number of patients changed from 120 to 30 as reported by ClinicalTrials.gov.
- 16 Jan 2008 New trial record.